TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Will the FDA Approve Allos Therapeutics' New Cancer Drug? The FDA advisory panel reviewing Genzyme's (GENZ) acute myeloid leukemia (AML) drug Clolar for elderly patients and Vion’s (VION.OB) leukemia drug Onrigin did not approve either drug. Genzyme’s ClolarComplete Story » seekingalpha.com |
Senators Reject Public Health Plan A Senate panel rejected the public health option, delivering a blow to the most controversial measure of the proposed overhaul. online.wsj.com |
Vaccine Output Falls Short Drug makers have shipped less than half the swine-flu vaccine expected this month due to production delays. online.barrons.com |
Scientist Finds Traits of a Killer in His Clan A neuroscientist who studies the biological basis of human behavior recently made a disquieting discovery: A member of his family has some of the traits of a psychopathic killer. online.wsj.com |
Protox Therapeutics: Positive Results for BPH Treatment Mike Havrilla submits:Protox Therapeutics (OTC: PTXRF.PK) applies genetic engineering techniques to create innovative, targeted protein-based therapeutics which are focused on prostate conditions and cancer. The Company's clinical-stage pipeline is based on the PORxin and INxin technology platforms. Lead drugs in clinical development include PRX302 for the treatment of benign prostatic hyperplasia (BPH or enlarged prostate) and localized prostate cancer as well as PRX321 for primary brain cancer (glioblastoma multiforme / GBM and astrocytoma).Protox announced positive top-line results this morning from its double-blinded placebo controlled Phase 2b TRIUMPH study of PRX302 in patients with moderate to severe benign prostatic hyperplasia (BPH). The study achieved its primary clinical endpoint of a statistically significant improvement in International Prostate Symptom Score (IPSS) at 90-days post-treatment for patients treated with PRX302 versus subjects receiving placebo. IPSS is a validated primary clinical endpoint used to assess the treatment benefit in BPH trials, and the index is measured on a 0-35 scale (with 0 = no problems, 35 = severe symptoms).Complete Story » seekingalpha.com |